Myasthenia gravis (MG) is an autoimmune disease characterized by impaired signal transmission at the neuromuscular junction, caused by auto antibodies targeting acetylcholine receptors (AChR) on skeletal muscle. This disrupts muscle contraction and leads to progressive fatigue and weakness.
To better model MG pathogenesis and therapeutic strategies, we established a humanized NCG mouse model of MG by intraperitoneal injection of peripheral blood lymphocytes (PBLs) from MG patients into immunodeficient NCG mice. This novel patient-derived MG model can recapitulate key immunopathological and histological characteristics of MG patients, presenting as a valuable translational tool for studying disease mechanisms and evaluating potential therapeutic interventions for MG.